Best of ASCO - 2014 Annual Meeting

 

Welcome

Anal Cancer

Gastrointestinal (Colorectal) Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
5-year survival following radiotherapy in anal cancer audit in a single center.

Stacie Joanne Morgan

e15070

Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase II study with panitumumab (FFCD 0904).

Thomas Aparicio

3570

Chemoradiotherapy for anal cancer: A population-based study of treatment interruption, treatment completion, and associated outcomes.

Michael J. Raphael

3573

Factors affecting differential outcomes in the definitive treatment of anal cancer between HIV+ and HIV- patients.

Matthew Susko

3572

Human papillomavirus, radiation dose and survival of patients with anal cancer.

Rafi Kabarriti

e15071

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—First experimental arm (EA) initial results.

Thomas J. George

3505

Outcomes of salvage surgery for anal squamous cell carcinoma: A systematic review and meta-analysis.

David Patrick Cyr

3571

Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer: NSABP FR-2.

Thomas J. George

TPS3620

Serial ctDNA analysis as a real-time indicator of neoadjuvant chemoradiotherapy in rectal cancer.

Jiaolin Zhou

3569

Tumor and microenvironment evolution during chemotherapy combine with bevacizumab in colorectal cancer liver metastasis.

Wangjun Liao

3568